Your Three EDGE For HUGE Gains
Dear Esteemed Investors,
Let me ask you this question:?Do you know why some investors/traders bank BIG while others are left holding bags??
If you don't know me, I'm Dr. Harvey Tran, Founder/CEO of the private biotech investment group,?Integrated BioSci Investing:?The #1 Biotech Service for Growth Investing and Power Catalysts Trading
As a physician-scientist, I eat, breathe, and live biotech, which gives me?an EDGE?in biotech investing/trading. And, I'm super excited in bringing that advantage to assist and serve you.
In this blog, I'll share with you how to develop your three BIGGEST EDGE. That way, you can write your own success story with biotech trading and investing.
With significant initial starting capital, you can get your sailing yacht to enjoy the high sea.
Before we dive into those three developments, you should realize why this is crucial.
If you think about it, you can only expect to perform like everyone else without an advantage.
For example, if your arm length is the same as the guy next to you, you'll only be able to reach as far. To go far and beyond, you want it to be longer.
As you can appreciate, your metaphorical arm length is like your EDGE in the market.
It determines how far or how much profit you can gain.
Shifting gears, let us dive into three EDGE that you can develop to boost your portfolio returns.
EDGE #1: Forecasting Binary Outcomes
The first and foremost is to "forecast" biotech binary events.
If you don't forecast in biotech, it's like you're driving on the highway blindfolded. You'd never know when you'd be hit by a MACK truck.
Now, if you can forecast biotech binary events with a reasonable degree of certainty, you would outperform the market.
As the first and only Private Biotech Investing Group that forecast and tracks our records over time, various positive binary developments over the years helped us enjoy market outperformance.
As you can see, a binary event is simply a "do or die" fundamental development for a biotech company. That typically entails either a BIG data release or FDA approval.?
Depending on the stock, a positive event usually but not always spark a robust rise. Conversely, a failed event is nearly certain to crash your stock.
If you continually do Power Trade these catalysts, your gains would add up over time.
For your long-term growth investing, you want to focus on stocks with a high likelihood of posting positive binary developments.
For instance,?ImmunoGen?(IMGN) had a recent positive MIRASOL data event which lead to a 140% pop in a single trading session.
Members who attended our recent weekly Open-Mic Webinar and followed our community chat learned about this play.?
And that allowed them to build shares in advance of the data release. Other members also have this stock in their long-term portfolio way before this event.
In addition to ImmunoGen, there are just?many more?for you to check out.
EDGE #2: Be Opportunistic
In investing as well as in life, the early bird gets the metaphorical worm.
Imagine when you were younger, had you moved outside of your comfort zone and asked the girl next door out, she could have been your wife.
Biotech investing is similar. You need t be opportunistic. And, being opportunistic ties into capturing fundamental stocks with upcoming binary events.?
If you're opportunistic, you can see that?Reata Pharmaceuticals?(RETA) had a pending drug approval catalyst earlier this year.
领英推荐
The other thing about being opportunistic is to keep tabs on "sector and sub-sector" rotation.
Depending on economic conditions, Wall Street often rotates or moves money into different sectors.
When money flowed out of biotech in the prior years, biotech encountered a significant downturn.
However, you can see that much more money is going into biotech this year. Therefore, you can take advantage of the opportunity to build shares in fundamentally robust companies now.
Here's an example of sub-sector rotation that we also discussed in our Open-Mic Webinary.
As you can appreciate, more capital has been redistributed to the non-alcoholic steatohepatitis (i.e., NASH) sub-sector.?
From the figure below, you can see that our BIG NASH stocks - Viking (VKTX), 89Bio (ETNB), Akero (AKRO), and Madrigal (MDGL) all increased multiple folds recently.
Notably, a sector or sub-sector rotation is usually caused by certain catalytic events.
For NASH, the?robust Phase 3 (MAESTRO-NASH) data of?Madrigal Pharmaceuticals?(MDGL) is the fuel that lit up this space.
Beyond NASH, there is another sub-sector rotation that we've been discussing inside Integrated BioSci Investing that allows our members to build their shares.
EDGE #3: Be Patient
Now, this is the most important trait because not all positive binary events lead to an immediate pop.
You can see that Briumvi's approval of TG Therapeutics (TGTX) requires time before the share price is substantially appreciated.?
Similarly, you can expect that the recent Seres Therapeutics (MCRB) approval of Vowsts would take time to rise.
Given that our stocks are extremely high quality, you can roll the ones without their catalyst hit into your long-term position.?
Let them bake in the oven while you are evaluating your next plays. Don't watch it. A watch stock won't boil.
See what our members are saying ... There's?much more here?since 2017.
As such, we're offering you our?no-obligation 2-week FREE trial?to begin your biotech winning process.
To your success,
Harvey Tran, MD
Analyst's Disclosure:?I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.
As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, I'm not giving you professional medical advice. Before embarking on any health-changing behavior, make sure you consult with your own doctor.
Seeking Alpha's Disclosure:?Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.